Zev Wainberg

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)HS Clinical Professor, Surgery


    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers (Basel). 2024 Mar 28; 16(7). Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer U. PMID: 38611000; PMCID: PMC11010910.
      View in: PubMed   Mentions:
    2. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024 Apr; 21(4):312-329. Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. PMID: 38424198.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023. Gastric Cancer. 2024 Feb 22. Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F, Bhandari P, Kawakubo H, Kodera Y, Terashima M, Muro K, Takeuchi H, Mansfield PF, Kurokawa Y, So J, Mönig SP, Shitara K, Rha SY, Janjigian Y, Takahari D, Chau I, Sharma P, Ji J, de Manzoni G, Nilsson M, Kassab P, Hofstetter WL, Smyth EC, Lorenzen S, Doki Y, Law S, Oh DY, Ho KY, Koike T, Shen L, van Hillegersberg R, Kawakami H, Xu RH, Wainberg Z, Yahagi N, Lee YY, Singh R, Ryu MH, Ishihara R, Xiao Z, Kusano C, Grabsch HI, Hara H, Mukaisho KI, Makino T, Kanda M, Booka E, Suzuki S, Hatta W, Kato M, Maekawa A, Kawazoe A, Yamamoto S, Nakayama I, Narita Y, Yang HK, Yoshida M, Sano T. PMID: 38386238.
      View in: PubMed   Mentions: 1     Fields:    
    4. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrospective multi-institutional analysis. Surgery. 2024 May; 175(5):1377-1385. Shimizu T, Maeda S, Link J, Deranteriassian A, Premji A, Verma A, Chervu N, Park J, Girgis M, Benharash P, Hines J, Wainberg Z, Wolfgang C, Burns W, Yu J, Fernandez-Del Castillo C, Lillemoe K, Ferrone C, Donahue T. PMID: 38365548.
      View in: PubMed   Mentions:    Fields:    
    5. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 Feb 03. Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Zahlten-Kümeli A, Taylor K, Enzinger PC. PMID: 38308771.
      View in: PubMed   Mentions:    Fields:    
    6. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024 Feb; 30(2):531-542. Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, Tavares AM, Seenappa LM, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, O'Reilly EM. PMID: 38195752; PMCID: PMC10878978.
      View in: PubMed   Mentions: 1     Fields:    Translation:CTClinical Trials
    7. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103). J Clin Pharmacol. 2023 Dec 17. Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. PMID: 38105505.
      View in: PubMed   Mentions:    Fields:    
    8. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. Oncologist. 2023 Dec 11; 28(12):e1209-e1218. Van Cutsem E, Yaeger R, Delord JP, Tabernero J, Siu LL, Ducreux M, Siena S, Elez E, Kasper S, Zander T, Steeghs N, Murphy D, Edwards M, Wainberg ZA. PMID: 37597246; PMCID: PMC10712701.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    9. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 01; 9(11):1574-1582. Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC. PMID: 37768658; PMCID: PMC10540058.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov; 24(11):1181-1195. Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS, KEYNOTE-859 investigators. PMID: 37875143.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    11. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 10 07; 402(10409):1272-1281. Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. PMID: 37708904.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    12. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 07; 24(7):744-756. Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. PMID: 37329891.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    13. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023 06 07; 14(1):3332. Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S, DESTINY-CRC01 investigators. PMID: 37286557; PMCID: PMC10247780.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    14. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. J Immunother Cancer. 2023 06; 11(6). Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, Chung HC, Muro K, Goekkurt E, McDermott RS, Mansoor W, Wainberg ZA, Shih CS, Kobie J, Nebozhyn M, Cristescu R, Cao ZA, Loboda A, Özgüroglu M. PMID: 37399357; PMCID: PMC10314681.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    15. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023 05; 29(5):1103-1112. Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. PMID: 37059834; PMCID: PMC10202803.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    16. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Cell Rep Med. 2023 04 18; 4(4):101013. Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, Bhambhvani H, Smith K, Johansen JS, Makawita S, Musher B, Mehta A, Hendifar A, Wainberg Z, Sohal D, Fountzilas C, Singhi A, Rajpurkar P, Collisson EA. PMID: 37044094; PMCID: PMC10140610.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting. Clin Cancer Res. 2023 04 03; 29(7):1360-1367. Wainberg ZA, Xie J, Valderrama A, Yin L, Zhang S, Shih CS, Bhagia P, Gu Q, Shitara K, Janjigian YY, Tabernero J. PMID: 36652563.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. J Gastric Cancer. 2023 Apr; 23(2):289-302. Ogata T, Narita Y, Wainberg ZA, Van Cutsem E, Yamaguchi K, Piao Y, Zhao Y, Peterson PM, Wijayawardana SR, Abada P, Chatterjee A, Muro K. PMID: 37129153; PMCID: PMC10154140.
      View in: PubMed   Mentions: 2  
    19. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023; 15:265-275. Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. PMID: 36969544; PMCID: PMC10032141.
      View in: PubMed   Mentions:
    20. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023 03 02; 141(9):996-1006. Kreitman RJ, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet AS, Wainberg ZA, Stein A, Dietrich S, de Jonge MJA, Willenbacher W, De Grève J, Arons E, Ilankumaran P, Burgess P, Gasal E, Subbiah V. PMID: 36108341; PMCID: PMC10163281.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    21. Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas. ESMO Open. 2023 04; 8(2):100778. Klempner SJ, Janjigian YY, Wainberg ZA. PMID: 36791669; PMCID: PMC9958250.
      View in: PubMed   Mentions: 2  Translation:Humans
    22. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol. 2023 03 01; 41(7):1470-1491. Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. PMID: 36603169.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    23. Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clin Cancer Res. 2023 01 04; 29(1):40-49. Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, Von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ. PMID: 36136304.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    24. Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 Jan; 128(2):400. Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. PMID: 36697966; PMCID: PMC9902525.
      View in: PubMed   Mentions:    Fields:    
    25. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. Cancer Treat Rev. 2023 Feb; 113:102502. Dayyani F, Macarulla T, Johnson A, Wainberg ZA. PMID: 36641880.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 01; 128(1):30-41. Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. PMID: 36335217; PMCID: PMC9814742.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    27. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov; 23(11):1430-1440. Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. PMID: 36244398.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    28. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS One. 2022; 17(10):e0276211. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. PMID: 36215283; PMCID: PMC9550092.
      View in: PubMed   Mentions:    Fields:    
    29. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clin Cancer Res. 2022 08 15; 28(16):3489-3498. Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Chao J, Wainberg ZA, Cao ZA, Aurora-Garg D, Kobie J, Cristescu R, Bhagia P, Shah S, Tabernero J, Shitara K, Wyrwicz L. PMID: 35657979.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    30. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022 Sep; 18(27):3011-3020. Strickler JH, Cubillo A, Liang JT, Matrana M, Kozloff M, Lowe T, Blaney M, Sahtout M, Naumovski L, Wainberg ZA. PMID: 35920133.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    31. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022 06; 28(6):1167-1177. Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. PMID: 35662283; PMCID: PMC9205784.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    32. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun; 18(20):2465-2473. Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. PMID: 35535555.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    33. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Curr Med Res Opin. 2022 08; 38(8):1295-1303. Kim G, Cockrum P, Surinach A, Wang S, Wainberg Z. PMID: 35354375.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. J Clin Oncol. 2022 08 01; 40(22):2458-2467. Maron SB, Moya S, Morano F, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, Yoshino T, Shitara K, Nakamura Y, Saeed A, Kasi PM, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, Pietrantonio F, Klempner SJ, Catenacci DVT. PMID: 35349370; PMCID: PMC9467681.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment. Br J Clin Pharmacol. 2022 07; 88(7):3392-3403. Guo C, Yu Y, Chakrabarti J, Piha-Paul SA, Moroose R, Plotka A, Shi H, Durairaj C, Wang DD, Wainberg ZA. PMID: 35236002; PMCID: PMC9314093.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    36. CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. Future Oncol. 2022 Apr; 18(12):1449-1459. Peterfy C, Chen Y, Countryman P, Chmielowski B, Anthony SP, Healey JH, Wainberg ZA, Cohn AL, Shapiro GI, Keedy VL, Singh A, Puzanov I, Wagner AJ, Qian M, Sterba M, Hsu HH, Tong-Starksen S, Tap WD. PMID: 35040698.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 04; 33(4):406-415. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. PMID: 35026411; PMCID: PMC9338780.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    38. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS One. 2021; 16(12):e0261994. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. PMID: 34941969; PMCID: PMC8699912.
      View in: PubMed   Mentions: 2     Fields:    
    39. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. J Immunother Cancer. 2021 12; 9(12). Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya M, Inzunza D, Liu J, Patterson SD, Zhou J, He J, Thai D, Bhargava P, Brachmann CB, Cantenacci DVT. PMID: 34893523; PMCID: PMC8666898.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    40. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021 12; 10(12):1550-1563. Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. PMID: 34750990; PMCID: PMC8674005.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    41. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Surgery. 2022 05; 171(5):1379-1387. Maeda S, Mederos MA, Chawla A, Moore AM, Shoucair S, Yin L, Burkhart RA, Cameron JL, Park JY, Girgis MD, Wainberg ZA, Hines OJ, Fernandez-Del Castillo C, Qadan M, Lillemoe KD, Ferrone CR, He J, Wolfgang CL, Burns WR, Yu J, Donahue TR. PMID: 34774289.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer. 2021 Nov; 24(6):1341. Van Cutsem E, Amonkar M, Fuchs CS, Alsina M, Özgüroglu M, Bang YJ, Chung HC, Muro K, Goekkurt E, Benson AB, Sun W, Wainberg ZA, Norquist JM, Chen X, Shih CS, Shitara K. PMID: 34536168; PMCID: PMC9172792.
      View in: PubMed   Mentions:    Fields:    
    43. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. Clin Cancer Res. 2022 01 15; 28(2):298-307. Tap WD, Singh AS, Anthony SP, Sterba M, Zhang C, Healey JH, Chmielowski B, Cohn AL, Shapiro GI, Keedy VL, Wainberg ZA, Puzanov I, Cote GM, Wagner AJ, Braiteh F, Sherman E, Hsu HH, Peterfy C, Gelhorn HL, Ye X, Severson P, West BL, Lin PS, Tong-Starksen S. PMID: 34716196.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. How quality of life can inform management decisions in later-line metastatic colorectal cancer. Clin Adv Hematol Oncol. 2021 Oct; 19 Suppl 22(10):1-16. Bekaii-Saab TS, Raghav K, Wainberg ZA. PMID: 35289802.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Quality-of-life factors impacting selection of third-line treatment in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2021 Oct; 19 Suppl 22(10):10-13. Wainberg ZA. PMID: 35289805.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. How quality of life can inform management decisions in later-line metastatic colorectal cancer: Q&A. Clin Adv Hematol Oncol. 2021 Oct; 19 Suppl 22(10):13-14. Bekaii-Saab TS, Raghav K, Wainberg ZA. PMID: 35289806.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Oncologist. 2021 10; 26(10):e1704-e1729. Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E. PMID: 34288262; PMCID: PMC8488781.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    48. A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. Clin Cancer Res. 2022 01 01; 28(1):84-94. Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M, Hagopian A, Andes R, Sauer L, Brackert SR, Chow W, DeMatteo R, Eilber FC, Glaspy JA, Chmielowski B. PMID: 34407970.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    49. Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery. ESC Heart Fail. 2021 10; 8(5):4301-4306. Stein-Merlob AF, Hsu JJ, Colton B, Berg CJ, Ferreira A, Price MM, Wainberg Z, Baas AS, Deng MC, Parikh RV, Yang EH. PMID: 34390221; PMCID: PMC8497199.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    50. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer. 2021 11; 24(6):1330-1340. Van Cutsem E, Amonkar M, Fuchs CS, Alsina M, Özgüroglu M, Bang YJ, Chung HC, Muro K, Goekkurt E, Benson AB, Sun W, Wainberg ZA, Norquist JM, Chen X, Shih CS, Shitara K. PMID: 34363528; PMCID: PMC8502140.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    51. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021 10; 20(10):1988-1995. Gordon MS, Nemunaitis J, Barve M, Wainberg ZA, Hamilton EP, Ramanathan RK, Sledge GW, Yue H, Morgan-Lappe SE, Blaney M, Kasichayanula S, Motwani M, Wang L, Naumovski L, Strickler JH. PMID: 34315767.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    52. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2022 Feb; 63(2):199-204. Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. PMID: 34272317.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    53. Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study. Acad Radiol. 2021 11; 28 Suppl 1:S210-S217. Haber Z, Lee EW, Price M, Wainberg Z, Hecht JR, Sayre J, Padia SA. PMID: 34099386.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021 Jun 01; 7(6):895-902. Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. PMID: 33792646; PMCID: PMC8017478.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    55. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021 07; 151:14-24. Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. PMID: 33957442.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    56. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 06; 22(6):779-789. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T, DESTINY-CRC01 investigators. PMID: 33961795.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCTClinical Trials
    57. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discov. 2021 09; 11(9):2158-2167. Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. PMID: 33910927; PMCID: PMC8418997.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    58. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 03 20; 39(9):990-1000. Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. PMID: 33577358; PMCID: PMC8078292.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    59. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh). 2021 Mar; 8(6):2002147. Liu X, Jiang J, Liao YP, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Liu Q, Chang CH, Wainberg ZA, Nel AE, Meng H. PMID: 33747719; PMCID: PMC7967046.
      View in: PubMed   Mentions: 21     Fields:    
    60. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Clin Cancer Res. 2021 04 01; 27(7):1923-1931. Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ, Chung HC, Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-Batran SE, Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J. PMID: 33446564.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    61. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 01; 22(1):118-131. O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH. PMID: 33387490.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    62. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist. 2021 03; 26(3):e414-e424. Cascinu S, Bodoky G, Muro K, Van Cutsem E, Oh SC, Folprecht G, Ananda S, Girotto G, Wainberg ZA, Miron MLL, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A. PMID: 33274542; PMCID: PMC7930430.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    63. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021 03 20; 39(9):966-977. Moehler M, Dvorkin M, Boku N, Özgüroglu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coskun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. PMID: 33197226; PMCID: PMC8078426.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCTClinical Trials
    64. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2021 03 15; 127(6):884-893. Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, Healey JH, van de Sande MAJ, Bernthal NM, Staals EL, Peterfy CG, Frezza AM, Hsu HH, Wang Q, Shuster DE, Stacchiotti S. PMID: 33197285; PMCID: PMC7946703.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    65. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. J Surg Oncol. 2021 Feb; 123(2):389-398. Park JY, King J, Reber H, Joe Hines O, Mederos MA, Wang HL, Dawson D, Wainberg Z, Donahue T, Girgis M. PMID: 33146409.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    66. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply. Lancet Oncol. 2020 11; 21(11):e516. Subbiah V, Lassen U, Gasal E, Burgess P, Wainberg ZA. PMID: 33152307.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1571-1580. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. PMID: 32880601; PMCID: PMC7489405.
      View in: PubMed   Mentions: 361     Fields:    Translation:HumansCTClinical Trials
    68. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. Oncologist. 2020 11; 25(11):954-962. Bendell J, Sharma S, Patel MR, Windsor KS, Wainberg ZA, Gordon M, Chaves J, Berlin J, Brachmann CB, Zavodovskaya M, Liu J, Thai D, Bhargava P, Shah MA, Khan SA, Starodub A. PMID: 32812320; PMCID: PMC7648353.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    69. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. PMID: 32910338; PMCID: PMC8944136.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    70. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020 09; 137:272-284. Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC. PMID: 32827847.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    71. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. PMID: 32818466.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCTClinical Trials
    72. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer. 2020 Jul 08; 20(1):633. Wainberg ZA, Feeney K, Lee MA, Muñoz A, Gracián AC, Lonardi S, Ryoo BY, Hung A, Lin Y, Bendell J, Hecht JR. PMID: 32641104; PMCID: PMC7346629.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    73. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 09 15; 26(18):4814-4822. Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. PMID: 32554514.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    74. Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation. Small. 2020 09; 16(36):e2000673. Liu X, Tang I, Wainberg ZA, Meng H. PMID: 32406992; PMCID: PMC7486239.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    75. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol. 2020 07 20; 38(21):2418-2426. Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, Deng W, Powers J, Wainberg ZA. PMID: 32167861; PMCID: PMC7367551.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    76. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 03; 127:150-157. Van Cutsem E, Muro K, Cunningham D, Bodoky G, Sobrero A, Cascinu S, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A, RAINBOW Investigators. PMID: 32014812.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    77. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2019 12 01; 30(12):2016. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. PMID: 31893488; PMCID: PMC8902979.
      View in: PubMed   Mentions: 2     Fields:    
    78. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2020 02 15; 26(4):846-854. Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. PMID: 31676670; PMCID: PMC7748730.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    79. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol. 2019; 3. Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AAL, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris V. PMID: 33015522; PMCID: PMC7526699.
      View in: PubMed   Mentions: 14     Fields:    
    80. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol. 2019; 9:849. García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. PMID: 31616627; PMCID: PMC6763619.
      View in: PubMed   Mentions: 57  
    81. Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma. Pancreas. 2019 08; 48(7):876-882. Kassardjian A, Stanzione N, Donahue TR, Wainberg ZA, Damato L, Wang HL. PMID: 31268985.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. Br J Cancer. 2019 08; 121(4):318-324. Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL. PMID: 31303643; PMCID: PMC6738068.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    83. Ramucirumab plus pembrolizumab: can we make the maths work? Lancet Oncol. 2019 08; 20(8):1041-1043. Klempner SJ, Wainberg ZA. PMID: 31301961.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors. Anticancer Drugs. 2019 06; 30(5):523-532. Hoffman J, Chakrabarti J, Plotka A, Milillo Naraine A, Kanamori D, Moroose R, Nguyen L, Wang D, Wainberg ZA. PMID: 30875341; PMCID: PMC6485310.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    85. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. PMID: 31126960; PMCID: PMC7376746.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    86. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun; 15(18):2073-2082. Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z. PMID: 31094225.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    87. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019 07; 22(4):828-837. Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. PMID: 30911859; PMCID: PMC6570680.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCTClinical Trials
    88. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 03; 20(3):420-435. Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA, RAINFALL Study Group. PMID: 30718072.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCTClinical Trials
    89. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2019 02; 108:17-24. Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA. PMID: 30592991.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    90. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer. ACS Nano. 2019 01 22; 13(1):38-53. Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH, Wang X, Tang I, Zheng E, Qiu W, Wainberg ZA, Nel AE, Meng H. PMID: 30525443; PMCID: PMC6554030.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    91. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist. 2019 04; 24(4):475-482. Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT. PMID: 30470690; PMCID: PMC6459251.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    92. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. Future Oncol. 2019 Feb; 15(6):567-577. Moehler M, Ryu MH, Dvorkin M, Lee KW, Coskun HS, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ. PMID: 30379568.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    93. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 05 10; 4(5):e180013. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. PMID: 29543932; PMCID: PMC5885175.
      View in: PubMed   Mentions: 811     Fields:    Translation:HumansCTClinical Trials
    94. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018; 3(4):e000353. Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D. PMID: 29765773; PMCID: PMC5950648.
      View in: PubMed   Mentions: 31  
    95. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clin Cancer Res. 2018 08 15; 24(16):3829-3837. Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC. PMID: 29691300; PMCID: PMC7496223.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    96. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. Ann Surg Oncol. 2018 Apr; 25(4):1000-1008. Court CM, Ankeny JS, Sho S, Winograd P, Hou S, Song M, Wainberg ZA, Girgis MD, Graeber TG, Agopian VG, Tseng HR, Tomlinson JS. PMID: 29442211; PMCID: PMC5896564.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    97. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017 Dec; 12(6):775-785. Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. PMID: 29067643; PMCID: PMC5700209.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    98. Differences in Cancer-Specific Mortality of Right- Versus Left-Sided Colon Adenocarcinoma: A Surveillance, Epidemiology, and End Results Database Analysis. JCO Clin Cancer Inform. 2017 11; 1:1-9. Wang C, Wainberg ZA, Raldow A, Lee P. PMID: 30657397.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    99. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 01 01; 36(1):7-13. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. PMID: 29072975; PMCID: PMC5791845.
      View in: PubMed   Mentions: 346     Fields:    Translation:HumansCTClinical Trials
    100. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 10; 22(10):1281. García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. PMID: 29018169; PMCID: PMC5634779.
      View in: PubMed   Mentions: 3     Fields:    
    101. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017 Jun 01; 3(6):767-773. Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB. PMID: 27737436; PMCID: PMC5824322.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    102. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest. 2017 May 01; 127(5):2007-2018. Liu X, Lin P, Perrett I, Lin J, Liao YP, Chang CH, Jiang J, Wu N, Donahue T, Wainberg Z, Nel AE, Meng H. PMID: 28414297; PMCID: PMC5409788.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimals
    103. Sex-Specific Differences in Colon Cancer when Quality Measures Are Adhered to: Results from International, Prospective, Multicenter Clinical Trials. J Am Coll Surg. 2017 Jul; 225(1):85-92. Gaitonde SG, Nissan A, Protic M, Stojadinovic A, Wainberg ZA, Chen DC, Bilchik AJ. PMID: 28392435.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    104. Consideration of an association between performance status and ramucirumab efficacy. Ann Oncol. 2017 04 01; 28(4):902-903. Yoon HH, Bendell JC, Wainberg ZA. PMID: 28203696.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017 06; 7(6):610-619. van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. PMID: 28363909; PMCID: PMC5546207.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    106. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 04; 22(4):375-e30. García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. PMID: 28275117; PMCID: PMC5388369.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    107. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma. Oncologist. 2017 03; 22(3):241-e15. Benson AB, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, Kudrik F. PMID: 28246206; PMCID: PMC5344644.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    108. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 06; 7(6):620-629. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. PMID: 28242752; PMCID: PMC5905335.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCellsCTClinical Trials
    109. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28; 116(5):575-583. Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. PMID: 28152546; PMCID: PMC5344293.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    110. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10; 35(2):157-165. Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. PMID: 27870574; PMCID: PMC6865065.
      View in: PubMed   Mentions: 182     Fields:    Translation:HumansCTClinical Trials
    111. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016 12; 27(12):2196-2203. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. PMID: 27765757; PMCID: PMC7360144.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    112. Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. J Mol Diagn. 2016 09; 18(5):688-696. Court CM, Ankeny JS, Sho S, Hou S, Li Q, Hsieh C, Song M, Liao X, Rochefort MM, Wainberg ZA, Graeber TG, Tseng HR, Tomlinson JS. PMID: 27375074; PMCID: PMC5397706.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    113. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016 06 14; 114(12):1367-75. Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, Rochefort MM, Girgis MD, Yao J, Wainberg ZA, Muthusamy VR, Watson RR, Donahue TR, Hines OJ, Reber HA, Graeber TG, Tseng HR, Tomlinson JS. PMID: 27300108; PMCID: PMC4984454.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    114. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. PMID: 27269937; PMCID: PMC5569690.
      View in: PubMed   Mentions: 379     Fields:    Translation:HumansCTClinical Trials
    115. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. J Gastrointest Surg. 2016 07; 20(7):1331-42. Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, Donahue TR. PMID: 27114246; PMCID: PMC4919020.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    116. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2016 Feb 10; 34(5):443-51. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. PMID: 26628478.
      View in: PubMed   Mentions: 313     Fields:    Translation:HumansCTClinical Trials
    117. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015 Dec 01; 33(34):4039-47. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS. PMID: 26351344; PMCID: PMC5089161.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansCTClinical Trials
    118. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. J Surg Oncol. 2015 Sep; 112(4):396-402. Williams JL, Nguyen AH, Rochefort M, Muthusamy VR, Wainberg ZA, Dawson DW, Tomlinson JS, Hines OJ, Reber HA, Donahue TR. PMID: 26303811.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    119. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015 Jul 30; 373(5):428-37. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G. PMID: 26222558.
      View in: PubMed   Mentions: 218     Fields:    Translation:HumansCTClinical Trials
    120. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. Expert Opin Biol Ther. 2015; 15(8):1205-20. Wainberg ZA, Drakaki A. PMID: 26066903.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    121. Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial. J Am Coll Surg. 2015 Sep; 221(3):643-51; quiz 783-5. Protic M, Stojadinovic A, Nissan A, Wainberg Z, Steele SR, Chen DC, Avital I, Bilchik AJ. PMID: 26213360; PMCID: PMC4657939.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    122. Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol. 2015 Jul; 76(1):61-7. Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR. PMID: 25969130.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    123. Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging. J Gastrointest Surg. 2015 Jun; 19(6):999-1006. Lavotshkin S, Jalas JR, Torisu-Itakura H, Ozao-Choy J, Lee JH, Sim MS, Stojadinovic A, Wainberg Z, Bifulco CB, Fox BA, Bilchik AJ. PMID: 25808375; PMCID: PMC4720974.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    124. A single institution experience in compliance with universal screening for Lynch syndrome in colorectal cancer. J Gastrointest Surg. 2015 Mar; 19(3):543-50. Hill AL, Sumra KK, Russell MM, Yoo J, Ko CY, Hart S, Wainberg Z, Hecht JR, Lin AY. PMID: 25504462.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    125. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):730-8. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C. PMID: 25500057.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansCTClinical Trials
    126. Value of primary tumor gene signatures in colon cancer when national quality standards are adhered to: preliminary results of an international prospective multicenter trial. Ann Surg Oncol. 2015 Feb; 22(2):535-42. Bilchik AJ, Wainberg ZA, Nissan A, Slamon DJ, Protic M, Avital I, Chen HW, Chen D, Sim M, Elashoff D, Stojadinovic A. PMID: 25190115.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    127. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014 Aug; 132(8):1005-9. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA. PMID: 24852144.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    128. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis. J Geriatr Oncol. 2014 Oct 01; 5(4):368-75. Ward P, Hecht JR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Naeim A. PMID: 25002322.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    129. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun; 32(3):518-25. von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. PMID: 24458261; PMCID: PMC4045341.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    130. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest New Drugs. 2014 Jun; 32(3):510-7. Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, LoRusso PM. PMID: 24395457.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    131. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin Colorectal Cancer. 2013 Dec; 12(4):239-47. Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF. PMID: 24188685.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    132. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol Syst Biol. 2013 Oct 08; 9:696. Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH, Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, Datti A, Babu M, Emili A, Pelletier L, Wrana J, Wainberg Z, Kim PM, Rottapel R, O'Brien CA, Andrews B, Boone C, Moffat J. PMID: 24104479; PMCID: PMC3817404.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    133. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec; 12(4):248-54. Wainberg ZA, Messersmith WA, Peddi PF, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Kozloff MF. PMID: 24075777.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    134. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol. 2013 Dec; 20(13):4322-9. Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, Hines OJ, Donahue TR, Reber HA, Tomlinson JS. PMID: 23943022.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    135. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2013 Oct; 4(4):302-9. Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Hecht JR. PMID: 24472472.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    136. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013; 8(3):e54014. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. PMID: 23516391; PMCID: PMC3597709.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCTClinical Trials
    137. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 2013 Apr; 12(4):509-19. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. PMID: 23395886.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    138. Time-dependent trends in lymph node yield and impact on adjuvant therapy decisions in colon cancer surgery: an international multi-institutional study. Ann Surg Oncol. 2012 Dec; 19(13):4178-85. Stojadinovic A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard RS, Steele SR, Peoples GE, Bilchik A. PMID: 22805869.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    139. Adjuvant treatment of early colon cancer with micrometastases: results of a national survey. J Surg Oncol. 2012 Aug 01; 106(2):119-22. Short SS, Stojadinovic A, Nissan A, Wainberg Z, Dhall D, Yao K, Bilchik A. PMID: 22308106; PMCID: PMC4657942.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    140. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012 Jan 14; 12:16. Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. PMID: 22244160; PMCID: PMC3292503.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    141. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer. 2011 Sep 06; 105(6):760-5. Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N, Hecht JR. PMID: 21811258; PMCID: PMC3171005.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    142. Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol. 2011 Mar; 12(1):46-60. Reddy D, Wainberg ZA. PMID: 21298375; PMCID: PMC3066394.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    143. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010 Dec; 16(12):1414-20. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. PMID: 21057494; PMCID: PMC3088104.
      View in: PubMed   Mentions: 164     Fields:    Translation:HumansAnimalsCells
    144. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Ann Surg. 2010 Sep; 252(3):467-74; discussion 474-6. Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard R, Elashoff D, Tyler J, Peoples GE, Stojadinovic A. PMID: 20739847; PMCID: PMC4364760.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    145. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010 Sep; 17(9):2312-20. Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. PMID: 20422460; PMCID: PMC2924500.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    146. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010 Mar 01; 16(5):1509-19. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. PMID: 20179222.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    147. Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res. 2009 Sep; 3(5):191-6. Chun P, Wainberg ZA. PMID: 20084160; PMCID: PMC2806802.
      View in: PubMed   Mentions: 11  
    148. Targeted lymph node evaluation in colorectal cancer: a decade of progress! J Surg Oncol. 2009 Apr 01; 99(5):273-4. Bilchik AJ, Stojadinovic A, Wainberg Z, Hecht JR. PMID: 19170087; PMCID: PMC4364757.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    149. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol. 2010 Mar-Apr; 28(2):180-8. Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RR. PMID: 19070520.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    150. Panitumumab in colorectal cancer. Expert Rev Anticancer Ther. 2007 Jul; 7(7):967-73. Wainberg ZA, Hecht JR. PMID: 17627455.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    151. Acute lymphoblastic leukemia presenting as acute renal failure. Nat Clin Pract Nephrol. 2007 Feb; 3(2):106-10. Suh WM, Wainberg ZA, de Vos S, Cohen AH, Kurtz I, Nguyen MK. PMID: 17251998.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    152. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther. 2006 Nov; 6(11):1229-35. Wainberg Z, Hecht JR. PMID: 17049019.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    153. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Jan; 5(5):363-7. Wainberg Z, Hecht JR. PMID: 16512997.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Zev's Networks
    Concepts (360)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (69)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California